These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38653365)

  • 21. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL.
    Wang Y; Snel M; Jonker JT; Hammer S; Lamb HJ; de Roos A; Meinders AE; Pijl H; Romijn JA; Smit JW; Jazet IM; Rensen PC
    Diabetes Care; 2011 Dec; 34(12):2576-80. PubMed ID: 21994427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative effect of glycaemic improvement on the components of diabetic dyslipidaemia: a longitudinal study.
    Wägner AM; Ordóñez-Llanos J; Caixàs A; Bonet R; de Leiva A; Pérez A
    Diabetes Res Clin Pract; 2005 Apr; 68(1):81-3. PubMed ID: 15811569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins.
    Vaverková H; Chlup R; Ficker L; Novotny D; Bartek J
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():74-7. PubMed ID: 9288551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus.
    Frénais R; Ouguerram K; Maugeais C; Mahot P; Charbonnel B; Magot T; Krempf M
    Atherosclerosis; 2001 Jul; 157(1):131-5. PubMed ID: 11427212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia.
    Saku K; Gartside PS; Hynd BA; Mendoza SG; Kashyap ML
    Metabolism; 1985 Aug; 34(8):754-64. PubMed ID: 3927110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.
    Aoki K; Kamiyama H; Takihata M; Taguri M; Shibata E; Shinoda K; Yoshii T; Nakajima S; Terauchi Y
    Endocr J; 2020 Sep; 67(9):957-962. PubMed ID: 32554954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of chronic renal failure on high-density lipoprotein kinetics.
    Fuh MM; Lee CM; Jeng CY; Shen DC; Shieh SM; Reaven GM; Chen YD
    Kidney Int; 1990 May; 37(5):1295-300. PubMed ID: 2111860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-density lipoprotein apolipoprotein A-I kinetics in obesity.
    Ooi EM; Watts GF; Farvid MS; Chan DC; Allen MC; Zilko SR; Barrett PH
    Obes Res; 2005 Jun; 13(6):1008-16. PubMed ID: 15976143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
    Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
    Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein abnormalities in well-treated type II diabetic patients.
    Manzato E; Zambon A; Lapolla A; Zambon S; Braghetto L; Crepaldi G; Fedele D
    Diabetes Care; 1993 Feb; 16(2):469-75. PubMed ID: 8432219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
    Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of apolipoprotein composition of high density lipoprotein particles on cholesteryl ester transfer protein activity. Particles containing various proportions of apolipoproteins AI and AII.
    Lagrost L; Perségol L; Lallemant C; Gambert P
    J Biol Chem; 1994 Feb; 269(5):3189-97. PubMed ID: 8106353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
    Taskinen MR; Björnson E; Matikainen N; Söderlund S; Pietiläinen KH; Ainola M; Hakkarainen A; Lundbom N; Fuchs J; Thorsell A; Andersson L; Adiels M; Packard CJ; Borén J
    Diabetes Obes Metab; 2021 May; 23(5):1191-1201. PubMed ID: 33502078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Reduction of lipoproteins with apoAI but without apoAII (LpAI) in non-insulin-dependent diabetic patients].
    Barkia A; Zouari N; Khrouf W; Ellouz F; Zouaghi H
    Ann Biol Clin (Paris); 1996; 54(2):83-6. PubMed ID: 8763631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes.
    Pappa E; Kostara C; Bairaktari E; Arvaniti E; Tsimihodimos V
    J Diabetes Complications; 2022 Oct; 36(10):108286. PubMed ID: 36115184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes.
    Albert SG; Oiknine RF; Parseghian S; Mooradian AD; Haas MJ; McPherson T
    Diabetes Care; 2007 Nov; 30(11):2800-3. PubMed ID: 17682119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.